[{"id":"cf414f6a-54f9-4ccf-b2fd-2b1f78958212","acronym":"INX-315-01","url":"https://clinicaltrials.gov/study/NCT05735080","created_at":"2023-02-21T16:01:43.523Z","updated_at":"2024-07-02T16:35:02.015Z","phase":"Phase 1/2","brief_title":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","source_id_and_acronym":"NCT05735080 - INX-315-01","lead_sponsor":"Incyclix Bio","biomarkers":" HER-2 • ER • CCNE1","pipe":" | ","alterations":" HER-2 negative • CCNE1 amplification","tags":["HER-2 • ER • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CCNE1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INX-315"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-22"}]